MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

Search

iRhythm Technologies Inc

Suletud

SektorTervishoid

164.11 0.72

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

160.89

Max

165.56

Põhinäitajad

By Trading Economics

Sissetulek

9M

-5.2M

Müük

6.2M

193M

Kasumimarginaal

-2.702

Töötajad

2,000

EBITDA

7.7M

2.4M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+36.16% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

19. veebr 2026

Turustatistika

By TradingEconomics

Turukapital

-484M

5.4B

Eelmine avamishind

163.39

Eelmine sulgemishind

164.11

Uudiste sentiment

By Acuity

50%

50%

174 / 360 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

iRhythm Technologies Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

22. jaan 2026, 21:55 UTC

Tulu

Capital One Financial Posts Higher 4Q Profit As Lending Increases

22. jaan 2026, 23:52 UTC

Tulu

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- Update

22. jaan 2026, 23:48 UTC

Market Talk

Nikkei May Rise as Tensions Between U.S. and Europe Ease -- Market Talk

22. jaan 2026, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Profit-Taking -- Market Talk

22. jaan 2026, 23:40 UTC

Market Talk

Spark NZ's Market Share Loss Concerns Bear -- Market Talk

22. jaan 2026, 23:30 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22. jaan 2026, 23:30 UTC

Market Talk

Genesis Energy Can Beat Newly Upgraded Earnings Goal -- Market Talk

22. jaan 2026, 22:37 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Capital One CEO: Brex Buy Reflects Business Payments Focus -- Market Talk

22. jaan 2026, 21:59 UTC

Omandamised, ülevõtmised, äriostud

Capital One Strikes $5.15 Billion Deal for Fintech Brex -- Update

22. jaan 2026, 21:50 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

22. jaan 2026, 21:44 UTC

Tulu

Self-Driving Stock Mobileye Plunged After Earnings. Here's Why. -- Barrons.com

22. jaan 2026, 21:32 UTC

Omandamised, ülevõtmised, äriostud

Capital One: Brex Invented Integrated Combination of Corporate Credit Cards, Spend Management Software and Banking in Single Platform >COF

22. jaan 2026, 21:31 UTC

Omandamised, ülevõtmised, äriostud

Capital One: Brex Is a Modern, AI-native Software Platform Offering Intelligent Finance Solutions >COF

22. jaan 2026, 21:31 UTC

Omandamised, ülevõtmised, äriostud

Capital One: Franceschi Will Continue to Lead Brex as Part of Capital One >COF

22. jaan 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

Capital One to Acquire Brex in Combination of Stk and Cash Transaction Valued at $5.15 B >COF

22. jaan 2026, 21:30 UTC

Tulu

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results -- WSJ

22. jaan 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

Capital One To Acquire Brex >COF

22. jaan 2026, 21:13 UTC

Tulu

Intel Returns to Losses in Q4 as It Ramps Up Spending on Chip Production -- WSJ

22. jaan 2026, 21:11 UTC

Tulu

Intuitive Surgical Sees 2026 Impact From Tariffs 1.2% of Revenue, Plus or Minus 10 Basis Points >ISRG

22. jaan 2026, 21:11 UTC

Tulu

Intuitive Surgical Sees 2026 Adjusted Gross Profit Margin 67%-68% >ISRG

22. jaan 2026, 21:10 UTC

Tulu

Intuitive Surgical Sees 2026 Worldwide Da Vinci Procedure Growth of 13%-15% >ISRG

22. jaan 2026, 21:06 UTC

Tulu

Capital One 4Q Total Non-Interest Expense Increased 13% to $9.3B >COF

22. jaan 2026, 21:05 UTC

Tulu

Capital One 4Q Provision for Credit Losses Increased $4.1B >COF

22. jaan 2026, 21:05 UTC

Tulu

Capital One 4Q Rev $15.58B >COF

22. jaan 2026, 21:05 UTC

Tulu

Capital One 4Q EPS $3.26 >COF

22. jaan 2026, 21:05 UTC

Tulu

Capital One 4Q Net Interest Margin 8.26% >COF

22. jaan 2026, 21:05 UTC

Tulu

Capital One 4Q Net $2.13B >COF

22. jaan 2026, 21:05 UTC

Tulu

Capital One 4Q Adj EPS $3.86 >COF

22. jaan 2026, 21:05 UTC

Tulu

Capital One 4Q Net Charge-Offs $3.8B >COF

22. jaan 2026, 21:05 UTC

Tulu

Intuitive Surgical 4Q EPS $2.21 >ISRG

Võrdlus sarnastega

Hinnamuutus

iRhythm Technologies Inc Prognoos

Hinnasiht

By TipRanks

36.16% tõus

12 kuu keskmine prognoos

Keskmine 222.83 USD  36.16%

Kõrge 244 USD

Madal 205 USD

Põhineb 14 Wall Streeti analüütiku instrumendi iRhythm Technologies Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

13

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

104.78 / 137.91Toetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

174 / 360 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest iRhythm Technologies Inc

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
help-icon Live chat